Loading...
•
Dec 31, 2023
Integra LifeSciences Q4 2023 Earnings Report
Integra LifeSciences reported a decrease in revenue and earnings for the fourth quarter of 2023, while highlighting progress in strategic initiatives.
Key Takeaways
Integra LifeSciences reported Q4 2023 revenues of $397.0 million, a decrease of 0.2% compared to Q4 2022. GAAP earnings per diluted share were $0.25, and adjusted earnings per diluted share were $0.89. The company is focusing on the Boston relaunch, global CereLink relaunch, SIA acquisition integration, and international portfolio expansion.
Reported revenues decreased by 0.2% to $397.0 million, with a 1.2% organic decline.
GAAP earnings per diluted share decreased to $0.25, compared to $0.63 in the prior year.
Adjusted earnings per diluted share decreased to $0.89, compared to $0.94 in the prior year.
Boston relaunch remains on track for mid-to-late Q2 2024.
Forward Guidance
For the full-year 2024, the Company expects revenues to be in a range of $1,603 million to $1,618 million, representing reported growth of approximately 4.0% to 5.0% and organic growth in the range of 4.0% to 5.0%. Adjusted earnings per diluted share are expected to be between $3.15 and $3.25.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...